American Association of Pharmaceutical Scientists Conference (AAPS) 2024 PharmSci 360
The AAPS PharmSci 360 Conference, organized by the American Association of Pharmaceutical Scientists (AAPS), is one of the premier events in the field of pharmaceutical sciences. It brings together professionals, researchers, and students from around the globe and is designed to offer comprehensive insights into the latest advancements and trends in pharmaceutical science.
Date: October 20-23, 2024
Location:Salt Palace Convention Center, Salt Lake City, UT
Booth: #1411
JOIN US!
From early phase development to clinical supply and commercial manufacturing, Catalent is dedicated to partnering with you to bring your molecule to market faster. We invite you to visit us at AAPS to explore our comprehensive solutions designed to advance your candidate from preclinical stages to commercial success. Complete the form to schedule a meeting with Catalent experts at AAPS.
FEATURED SPEAKING SESSIONS
Title: Softgels: The Missed Opportunity for Superior Bioavailability and Modulated Drug Release
Date: Monday, October 21, 2024
Time: 3:30 – 4:30 PM MDT
Location: Stage 2
Speaker: Karunakar (Karu) Sukuru, R.Ph., Ph.D.
Title: Optimizing Drug Delivery Strategies for Phase 1 Oral Development through Developability Assessment
Date: Monday, October 21, 2024
Time: 12:30 – 1:30 PM MDT
Location: Stage 4
Speaker: Lisa Caralli
Title: Strategic Advantages of Hot Melt Extrusion for Challenging APIs in Oral Dosage Forms
Date: Tuesday, October 22, 2024
Time: 12:30 – 1:15 PM MDT
Location: Stage A
Speaker: Hibreniguss Terefe, Ph.D.
Title: High-Dose Engineered Powder for CNS Therapy via Inhalation
Date: Wednesday, October 23, 2024
Time: 3:30 – 3:45 PM MDT
Location: 255 EF
Speaker: Alan Watts, Ph.D.
SPEAKERS
Karunakar (Karu) Sukuru, R.Ph., Ph.D.
Global Vice President-Rx Product Development
Pharma and Consumer Health
Catalent
Lisa Caralli
Senior Director of Scientific Advisory
Catalent
Hibreniguss Terefe, Ph.D.
Director of Research and Development
Catalent
Alan Watts, Ph.D.
Director Innovation and Partnerships
Orally Inhaled Delivery
Catalent
Related Topics
ABOUT CATALENT
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.
